{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:03:20Z","timestamp":1771553000606,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:00:00Z","timestamp":1551484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,6,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the management of localized anal canal squamous cell carcinomas is well established, the role of pelvic chemoradiation (CRT) in the treatment of patients presenting with synchronous metastatic (stage IV) disease is poorly defined. This study used a national cancer database to compare the overall survival (OS) rates of patients with synchronous metastatic disease receiving CRT to the pelvis and patients treated with chemotherapy (CT) alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included adult patients with anal canal squamous cell carcinomas presenting with synchronous metastases diagnosed from 2004 to 2012. Multiple imputation and 2:1 propensity score matching were used to create a matched data set for testing. The proportional hazards model was used to estimate the hazard ratio (HR) for the effect of the treatment group on OS. With only patients in the matched data set, the OS of the treatment groups was estimated with the Kaplan\u2010Meier method by treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study started with an unmatched data set of 978 patients, and 582 patients were selected for the matched data set: 388 in the CRT group and 194 in the CT\u2010alone group. The HR for the group effect was 0.75 (95% confidence interval [CI], 0.61\u20100.92;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.006). The median OS was 21.1\u00a0months in the CRT group (95% CI, 17.4\u201024.0\u00a0months) and 14.6\u00a0months in the CT group (95% CI, 12.2\u201018.4\u00a0months). The corresponding 5\u2010year OS rates were 23% (95% CI, 18%\u201028%) and 14% (95% CI, 7%\u201021%), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large series analyzing OS in patients with stage IV anal cancer, CRT was associated with improved OS in comparison with CT alone. Because of the lack of prospective data in this setting, this evidence will help to guide treatment approaches in this group of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.32017","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T10:37:34Z","timestamp":1551523054000},"page":"2115-2122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Database review"],"prefix":"10.1002","volume":"125","author":[{"given":"Yasser A.","family":"Abdelazim","sequence":"first","affiliation":[{"name":"Radiation Oncology Department National Cancer Institute, Cairo University Cairo Egypt"},{"name":"Department of Radiation Oncology Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel N.","family":"Rushing","sequence":"additional","affiliation":[{"name":"Biostatistics, Duke Cancer Institute Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Palta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Willett","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-767X","authenticated-orcid":false,"given":"Brian G.","family":"Czito","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605605"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70086-X"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.4837"},{"key":"e_1_2_8_8_1","first-page":"861","article-title":"5\u2010Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous\u2010cell anal cancer","volume":"86","author":"Faivre C","year":"1999","journal-title":"Bull Cancer"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","unstructured":"RaoS SclafaniF EngC et al.InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5\u2010fluorouracil (5\u2010FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment na\u00efve disease\u2014an International Rare Cancers Initiative (IRCI) trial. Paper presented at: European Society for Medical Oncology Meeting; October 19\u201023 2018; Munich Germany.","DOI":"10.1093\/annonc\/mdy424.022"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00263905"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80702-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-006-7667-x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-008-0467-3"},{"key":"e_1_2_8_15_1","first-page":"4637","article-title":"Single\u2010agent paclitaxel in advanced anal cancer after failure of cisplatin and 5\u2010fluorouracil chemotherapy","volume":"31","author":"Abbas A","year":"2011","journal-title":"Anticancer Res"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2563"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-009-0103-7"},{"key":"e_1_2_8_19_1","unstructured":"PathakP KingB OhinataA et al.The treatment of metastatic squamous cell carcinoma of the anal canal: a single institution experience. Paper presented at: ASCO Gastrointestinal Cancer Symposium: Multidisciplinary Approaches to the Prevention Diagnosis and Therapy of GI Cancers; January 25\u201027 2008; Orlando FL."},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/jco.2012.30.15_suppl.4060","article-title":"Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal [abstract 4060]","volume":"30","author":"Eng C","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2016.07.008"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9467-8"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.11.021"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.04.076"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1914"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.2040"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27825"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e31819eb7f0"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1203"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:57:31Z","timestamp":1761893851000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,2]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["10.1002\/cncr.32017"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32017","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,2]]},"assertion":[{"value":"2018-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}